BACKGROUND:Riboflavin (vitamin B(2)) is the precursor for FAD, the cofactor for methylenetetrahydrofolate reductase (MTHFR). MTHFR catalyzes the formation of 5-methyltetrahydrofolate, which acts as a methyl donor for homocysteine remethylation. Individuals with the MTHFR 677C-->T mutation have increased plasma total homocysteine (tHcy) concentrations, particularly in association with low folate status. It has been proposed that riboflavin may act together with folate to lower plasma tHcy, particularly in individuals with the thermolabile MTHFR T variant. METHODS: We measured B-vitamin status and plasma tHcy in 126 healthy individuals 20-63 years of age (42 CC, 42 CT, and 42 TT MTHFR genotypes) at baseline and after three interventions (4 months): placebo plus natural diet; daily 400 microg folic acid supplement plus natural diet; and increased dietary folate to 400 microg/day. RESULTS: At baseline and after nutritional intervention, lower riboflavin status was associated with increased plasma tHcy concentrations. Plasma tHcy was 2.6 micromol/L higher in the lowest plasma riboflavin quartile compared with the highest (P <0.02) and was 4.2 micromol/L higher in the highest erythrocyte glutathione reductase activation coefficient (EGRAC) quartile compared with the lowest (P <0.001). This effect was not restricted to those with the T allele. Folic acid given as a 400 microg/day supplement appeared to exacerbate a tendency toward riboflavin deficiency, as suggested by an increase in the proportion of individuals with EGRAC > or =1.4 from 52% to 65% after supplementation (P <0.05). CONCLUSIONS:Folate and riboflavin interact to lower plasma tHcy, possibly by maximizing the catalytic activity of MTHFR. The effect may be unrelated to MTHFR genotype.
RCT Entities:
BACKGROUND:Riboflavin (vitamin B(2)) is the precursor for FAD, the cofactor for methylenetetrahydrofolate reductase (MTHFR). MTHFR catalyzes the formation of 5-methyltetrahydrofolate, which acts as a methyl donor for homocysteine remethylation. Individuals with the MTHFR 677C-->T mutation have increased plasma total homocysteine (tHcy) concentrations, particularly in association with low folate status. It has been proposed that riboflavin may act together with folate to lower plasma tHcy, particularly in individuals with the thermolabile MTHFR T variant. METHODS: We measured B-vitamin status and plasma tHcy in 126 healthy individuals 20-63 years of age (42 CC, 42 CT, and 42 TT MTHFR genotypes) at baseline and after three interventions (4 months): placebo plus natural diet; daily 400 microg folic acid supplement plus natural diet; and increased dietary folate to 400 microg/day. RESULTS: At baseline and after nutritional intervention, lower riboflavin status was associated with increased plasma tHcy concentrations. Plasma tHcy was 2.6 micromol/L higher in the lowest plasma riboflavin quartile compared with the highest (P <0.02) and was 4.2 micromol/L higher in the highest erythrocyte glutathione reductase activation coefficient (EGRAC) quartile compared with the lowest (P <0.001). This effect was not restricted to those with the T allele. Folic acid given as a 400 microg/day supplement appeared to exacerbate a tendency toward riboflavin deficiency, as suggested by an increase in the proportion of individuals with EGRAC > or =1.4 from 52% to 65% after supplementation (P <0.05). CONCLUSIONS:Folate and riboflavin interact to lower plasma tHcy, possibly by maximizing the catalytic activity of MTHFR. The effect may be unrelated to MTHFR genotype.
Authors: Meng-Hua Tao; Joel B Mason; Catalin Marian; Susan E McCann; Mary E Platek; Amy Millen; Christine Ambrosone; Stephen B Edge; Shiva S Krishnan; Maurizio Trevisan; Peter G Shields; Jo L Freudenheim Journal: Nutr Cancer Date: 2011-09-14 Impact factor: 2.900
Authors: Chandrika J Piyathilake; Maria Azrad; Maurizio Macaluso; Gary L Johanning; Phillip E Cornwell; Edward E Partridge; Douglas C Heimburger Journal: Nutrition Date: 2007-02-14 Impact factor: 4.008
Authors: Jane C Figueiredo; A Joan Levine; Maria V Grau; Oivind Midttun; Per M Ueland; Dennis J Ahnen; Elizabeth L Barry; Shirley Tsang; David Munroe; Iqbal Ali; Robert W Haile; Robert S Sandler; John A Baron Journal: Cancer Epidemiol Biomarkers Prev Date: 2008-08 Impact factor: 4.254
Authors: Niels Gregersen; Brage S Andresen; Christina B Pedersen; Rikke K J Olsen; Thomas J Corydon; Peter Bross Journal: J Inherit Metab Dis Date: 2008-10-07 Impact factor: 4.982
Authors: Elizabeth A Williams; Mark Welfare; Alison Spiers; Marilyn H Hill; Wendy Bal; Eileen R Gibney; Yvonne Duckworth; Hilary J Powers; John C Mathers Journal: Eur J Nutr Date: 2012-12-28 Impact factor: 5.614